Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer
Status:
Unknown status
Trial end date:
2020-03-10
Target enrollment:
Participant gender:
Summary
this single arm，open-label，multi-center study is aimed to evaluate the efficiency of icotinib
in plasma ctDNA EGFR mutation-positive patients diagnosed with lung cancer